Lupin shares rise nearly 1% on launching authorised generic Ravicti oral liquid for urea cycle disorders in US

At 11:49 AM, Lupin shares were trading 0.31% lower at ₹1,933.80 apiece on the National Stock Exchange (NSE).

“Glycerol Phenylbutyrate Oral Liquid, 1.1g/mL is indicated for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone,” the company said in an exchange filing.

Earlier this month, on October 9, Lupin Limited launched a strategic partnership programme to widen the adoption of PrecisionSphere, a long-acting injectable (LAI) platform developed by its subsidiary Nanomi B.V.

The company said PrecisionSphere has demonstrated efficacy and safety in delivering medicines and is ready for commercial use following the US regulator’s approval of the first product developed with the platform.

On October 8, the company announced its plans for a new state-of-the-art pharmaceutical manufacturing plant in Coral Springs, a significant step in safeguarding the health and safety of Florida families and the nation.

Meanwhile, in a separate filing on October 4, the company’s Pithampur Unit-2 manufacturing facility received the 'Official Action Indicated (OAI) classification from the U.S. Food and Drug Administration (US FDA).

An OAI classification indicates that a facility is in an unacceptable state of compliance, according to the US FDA website.

Lupin share price details

In the past five trading sessions, Lupin’s shares have slipped 0.89% and fallen 2.80% over the past month. Over the last six months, the stock has dropped 8.03%, while on a year-to-date basis, it is down 18.17%.

The shares hit a 52-week high of ₹2,402.90 on January 2, 2025, and a 52-week low of ₹1,795.20 on April 7, 2025. As of October 24, Lupin’s market capitalisation stood at ₹88,327.84 crore.